TDR Research Initiating Coverage of Trulieve Cannabis
Trulieve Cannabis Corp. operates as a multi-state cannabis retailer, cultivating, processing, and manufacturing cannabis products. The company is headquartered in Quincy, Florida, and operates in multiple states, including Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. Trulieve’s product range includes flowers, edibles, vapes, creams, balms, lotions, vaporizers, batteries, cartridges, concentrates, topicals, capsules, syringes, tinctures, and accessories.
Download your report HERE
We rate Trulieve as a “Buy” based on our comprehensive analysis of its financial health and growth potential. Our valuation incorporates three key methods: Discounted Cash Flow (DCF) growth, DCF revenue, and EV/Revenue. The blended fair value of Trulieve is calculated to be $15.29, which represents a potential upside of 46% from its current price of $10.45. This significant potential for return is underpinned by Trulieve’s strong financial metrics, including its high current ratio and lower liabilities-to-assets ratio compared to peers.
Trulieve exhibits several strengths that enhance its attractiveness as an investment. The company demonstrates robust cost management and profitability, as reflected in its higher-than-average gross profit margin. Additionally, Trulieve has shown strong cash flow management, with a high Levered Free Cash Flow (LFCF) Margin and significant positive change over the last twelve months. These factors contribute to Trulieve’s financial flexibility and ability to invest in growth opportunities, pay dividends, and weather economic downturns.
However, Trulieve also faces some challenges compared to its peers. The company’s recent and long-term EBITDA growth is below industry averages, indicating areas for improvement in operational efficiency and profitability. The negative change in its gross profit margin and modest improvement in SG&A margin further highlight the need for better cost control. Additionally, Trulieve’s conservative approach to reinvestment, as evidenced by its lower Capital Expenditures (CapEx) Margin, may impact its future growth potential if not aligned with strategic growth objectives.
